Learn more about 2024 expectations of biopharma decision-makers in this forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries.
The 2024 Syneos Health Dealmakers’ Intentions Survey comes at a time of cautious optimism for the life sciences industry. Despite concerns about conditions for the market entering 2023, we have exited the year with an improved market environment, including upticks in closely-watched biotech indexes. As we look at the confluence of exciting AI milestones, weight loss advances and gene editing breakthroughs it seems that if macroeconomic conditions hold steady, there are brighter days ahead.
To better understand the current landscape of this marketplace, Syneos Health surveyed more than 100 members of the biopharma community, most of them with executive-level influence on decision making. This report, the 14th in our series, captures their expectations for deal activity, supply and demand for specific assets and different development stages, pitfalls leading to failure and other factors affecting dealmaking. What lies ahead for dealmaking in the biopharmaceutical industry in 2024?
Download the report to learn more.
Looking for exclusive insight?
